Contineum Therapeutics Inc-A 2026年季度报告

Washington, D.C. 20549_______________________________________________________________________ FORM 10-Q_______________________________________________________________________ For the quarterly period ended March 31, 2026 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-42001 Contineum Therapeutics, Inc.(Exact name of registrant as specified in its charter) _______________________________________________________________________ (858) 333-5280(Registrant’s telephone number, including area code) N/A(Former name, former address and former fiscal year, if changed since last report) Securities registered pursuant to Section 12(b) of the Act: Class A Common Stock, $0.001 par value per share Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of theSecurities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to filesuch reports), and (2) has been subject to such filing requirements for the past 90 days. YesNo Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files). YesNo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition periodfor complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YesNo As of April30, 2026, the registrant had 37,386,377 total shares outstanding, of which there were 32,723,877 shares of Class Acommon stock, $0.001 par value per share, outstanding and 4,662,500 shares of Class B common stock, $0.001 par value per share,outstanding. SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements concerning our business, operations and financialperformance and condition, as well as our plans, objectives and expectations for our business, operations and financial performanceand condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-lookingstatements. These statements involve known and unknown risks, uncertainties and other important factors that are in some casesbeyond our control and may cause our actual results, performance or achievements to be materially different from any future results,performance or achievements expressed or implied by the forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,”“plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these terms or other similarexpressions are intended to identify forward looking statements. Forward-looking statements contained in this report include, but arenot limited to, statements about: • the likelihood of our clinical trials demonstrating the safety and efficacy of our drug candidates; • the timing and progress of our current clinical trials, the expected results of these clinical trials and the timing of initiationof our planned and future clinical trials; • our plans relating to the clinical development of our current and future drug candidates, including the size, number anddisease indications to be evaluated; • Janssen Pharmaceutica NV, a Johnson & Johnson (“J&J”) company’s, plans related to the clinical development of PIPE-307; • our clinical translational approach, and our ability to identify and develop drug candidates that can potentially treatneuroscience, inflammation and immunology (“NI&I”) diseases by targeting biological pathways associated with specificclinical impairment to alter the course of disease; • the size of the market opportunities for our drug candidates; • the rate and degree of market acceptance and clinical utility of our drug candidates; • our plans relating to commercializing our drug candidates, if approved; • the success of competing therapies and technologies that are or may become available; • the beneficial characteristics, safety, efficacy, therapeutic effects and potential advantages of our drug candidates; • the timing or likelihood of regulator